We describe the successful enrollment, observation and data collection methods of the ongoing Palliative Care Communication Research Initiative (PCCRI).
We detail the successful PCCRI methods for enrollment, direct observation and data collection for this complex "field" environment.
The enrollment and clinical observations for this randomized controlled trial are as described previously [ 16].
Current mood symptoms were determined from patient report, as assessed by the STEP-BD Affective Disorders Evaluation at the time of enrollment, and clinician observation and reflected any mood symptoms in the 10 days prior to enrollment for the primary analysis, and mood symptoms thresholded for occurring on at least four or seven of the 10 days prior to enrollment for the secondary analysis.
The use of antiarrhythmic drugs, sympathomimetic drugs, sympatholytic drugs, defibrillator use, catheter ablation, and pacemaker therapy were prohibited from the enrollment until completing all observations at 2 h after starting treatment.
Of these, 27 (75%) patients remained in the study through week 24 of their illness, and 20 (56%) completed the entire 24 weeks of observation after enrollment.
The primary efficacy objective of this study was to assess the EFS, defined as the time from enrollment to the first observation of disease progression, death due to any cause, or early treatment discontinuation.
To ensure mainly prospective observation, retrospective enrollment was limited to patients who had begun treatment with everolimus up to 90 days before the start of the study or had undergone no more than one image-based follow-up since treatment initiation.
The study design was identical for both studies with 4 pens (physically identical), 2 treatments (Dragonhyde vs. formalin and Dragonhyde vs. copper sulfate), 2 periods (crossing over the treatment within pen), and 3 repeated measures (3 observations per cow: enrollment, wk 2, and wk 4).
*PYO, person-years of observation (based on enrollment characteristics).
